Co-Deletion of Chromosome 1p/19q and IDH1/2 Mutation in Glioma Subsets of Brain Tumors in Chinese Patients

OBJECTIVE: To characterize co-deletion of chromosome 1p/19q and IDH1/2 mutation in Chinese brain tumor patients and to assess their associations with clinical features. METHODS: In a series of 528 patients with gliomas, pathological and radiological materials were reviewed. Pathological constituents of tumor subsets, incidences of 1p/19q co-deletion and IDH1/2 mutation in gliomas by regions and sides in the brain were analyzed. RESULTS: Overall, 1p and 19q was detected in 339 patients by FISH method while the sequence of IDH1/2 was determined in 280 patients. Gliomas of frontal, temporal and insular origin had significantly different pathological constituents of tumor subsets (P<0.001). Gliomas of frontal origin had significantly higher incidence of 1p/19q co-deletion (50.4%) and IDH1/2 mutation (73.5%) than those of non-frontal origin (27.0% and 48.5%, respectively) (P<0.001), while gliomas of temporal origin had significantly lower incidence of 1p/19q co-deletion (23.9%) and IDH1/2 mutation (41.7%) than those of non-temporal origin (39.9% and 63.2%, respectively) (P = 0.013 and P = 0.003, respectively). Subgroup analysis confirmed these findings in oligoastrocytic and oligodendroglial tumors, respectively. Although the difference of 1p/19q co-deletion was not statistically significant in temporal oligodendroglial tumors, the trend was marginally significant (P = 0.082). However, gliomas from different sides of the brain did not show significant different pathological constituents, incidences of 1p/19q co-deletion or IDH1/2 mutation. CONCLUSION: Preferential distribution of pathological subsets, 1p/19q co-deletion and IDH1/2 mutation were confirmed in some brain regions in Chinese glioma patients, implying their distinctive tumor genesis and predictive value for prognosis

Analysis of CD137L and IL-17 Expression in Tumor Tissue as Prognostic Indicators for Gliblastoma

<p>Glioblastoma multiforme (GBM) is the most common form of malignant glioma, characterized by genetic instability and unpredictable clinical behavior. GBM is marked by an extremely poor prognosis with median overall survival of 12&#126;14 months. In this study, we detected the CD137L-expressing cells and IL-17-expressing cells in tumor tissues resected from patients with GBM. Expression of CD137L and IL-17 were assessed by immunohistochemistry, and the prognostic value of CD137L and IL-17 expression within the tumor tissues were assessed by Cox regression and Kaplan-Meier analysis. Immunohistochemical detection showed that positive cells of CD137L and IL-17 in glioblastoma tissue samples were 46.3% (19/ 41) and 73.2% (30/41) respectively. Expression of CD137L was not correlated with overall survival of GBM patients (<i>P=</i>0.594), while significantly longer survival rate was seen in patients with high expression of IL-17, compared to those with low expression of IL-17 (P=0.007). In addition, we also found that IL-17 expression was significantly correlated with Progression-free survival (PFS) (<i>P=</i>0.016) and death rate (<i>P=</i>0.01). Furthermore, multivariate Cox proportional hazard analyses revealed that IL-17 (<i>P=</i>0.018) and PFS (<i>P=</i>0.028) were independent factors affecting the overall survival probability. Kaplan-Meier analysis showed that PFS of high expression of IL-17 group were significantly longer (<i>P</i>=0.004) than low expression group with GBM. It is concluded that high levels of IL-17 expression in the tumor tissues may be a good prognostic marker for patients with GBM.</p

Analysis of CD137L and IL-17 Expression in Tumor Tissue as Prognostic Indicators for Gliblastoma

licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. Received: 2012.10.29; Accepted: 2013.01.15; Published: 2013.01.16 Glioblastoma multiforme (GBM) is the most common form of malignant glioma, characterized by genetic instability and unpredictable clinical behavior. GBM is marked by an extremely poor prognosis with median overall survival of 12∼14 months. In this study, we detected the CD137L-expressing cells and IL-17-expressing cells in tumor tissues resected from patients wit

Synergetic hydrogen-bond network of functionalized graphene and cations for enhanced atmospheric water capture

Water molecules at the solid-liquid interface display intricate behaviours sensitive to small changes. The presence of different interfacial components, such as cations or functional groups, shape the physical and chemical properties of the hydrogen bond network. Understanding such interfacial hydrogen-bond networks is essential for a large range of applications and scientific questions. To probe the interfacial hydrogen-bond network, atmospheric water capture is a powerful tool. Here, we experimentally observe that a calcium ion on a calcium-intercalated graphene oxide aerogel (Ca-GOA) surface captures 2.7 times more water molecules than in its freestanding state. From density functional theory (DFT) calculations, we uncover the synergistically enhanced hydrogen-bond network of the calcium ion-epoxide complex due to significantly larger polarizations and hydrogen bond enthalpies. This study reveals valuable insights into the interfacial water hydrogen-bond network on functionalized carbon-cation complexed surfaces and potential pathways for future atmospheric water generation technologies

Regional frequencies of 1p/19q co-deletion and IDH1/2 mutation in glioma subsets.

<p>A: astrocytomas; AA: anaplastic astrocytoma; G: glioblastoma; O: oligodendrogliomas; AO: anaplastic oligodedroglioma; OA: oligoastrocytomas; AOA: anaplastic oligoastrocytoma; IDH: isocitrate dehydrogenase gene; (-): no data available. Numbers of cases with alterations are given in respect to cases examined.</p

Gliomas of frontal and temporal origin had significantly different incidences of IDH1/2 mutation irrespective and in respective of tumor pathology.

<p>The regional incidences of IDH1/2 mutation in all gliomas of the region irrespective of pathology were labeled with “All”. The regional incidences of IDH1/2 mutation in respective of pathology were labeled with “A+AA, O+AO and OA+AOA” respectively. *The incidence of IDH1/2 mutation in this region is significantly higher or lower than that in other regions (p<0.05, chi-square test).</p

Regional molecular heterogeneity about chromosome 1p/19q and IDH1/2 in gliomas reported in English literature.

<p>Regional molecular heterogeneity about chromosome 1p/19q and IDH1/2 in gliomas reported in English literature.</p

Gliomas of frontal and temporal origin had significantly different incidences of 1p/19q co-deletion irrespective and in respective of tumor pathology.

<p>The regional incidences of 1p/19q co-deletion in all gliomas of the region irrespective of pathology were labeled with “All”. The regional incidences of 1p/19q co-deletion in respective of pathology were labeled with “A+AA+G, O+AO and OA+AOA” respectively. *The incidence of 1p/19q co-deletion in this region is significantly higher or lower than that in other regions (<i>p</i><0.05, chi-square test).</p